Mindfulness Intervention for Blood Cancers
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, it mentions that all participants will continue to receive their usual medical care, which suggests you may not need to stop your current medications.
What data supports the effectiveness of the treatment Nite2Day+ for blood cancers?
Is mindfulness intervention safe for people with cancer?
Research on mindfulness-based interventions for cancer patients suggests they are generally safe and can help reduce stress, improve sleep, and enhance quality of life. While these studies focus on different types of cancer, they indicate that mindfulness practices are well-tolerated and do not pose significant safety concerns.13678
How does the treatment Nite2Day+ differ from other treatments for blood cancers?
What is the purpose of this trial?
People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Participants will complete a baseline survey online, using a mobile application, or paper/pencil. Once the baseline survey is complete, participants will be randomized (like a flip of a coin) to receive Nite2Day+ or Standard Care. Nite2Day+ will include activities during and after inpatient treatment. During inpatient treatment, participants will use a mobile app to access: 1) mindfulness meditations, 2) brief sleep education videos, and 3) brief videos teaching strategies to improve sleep quality in the hospital. After inpatient treatment, participants will complete 6, videoconference sessions (45-60 minutes) with a trained therapist to learn mindfulness and behavioral coping strategies to self-manage nighttime sleep disturbance and daytime symptoms of fatigue, stress, and pain. Three follow-up surveys will occur at hospital discharge, and approximately 8, and 12 weeks after hospital discharge. Participants randomized to Nite2Day+ will be given the option to complete an exit interview to provide feedback on the Nite2Day+ program. Participants randomized to Standard Care will only complete the four surveys. All participants will continue to receive their usual medical care. The total study duration is about 16 weeks.
Eligibility Criteria
This trial is for hematologic cancer patients experiencing sleep disturbances and symptoms like fatigue, stress, and pain during/after inpatient treatment. Participants must be able to complete surveys and attend videoconference sessions post-treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Inpatient Treatment
Participants use a mobile app to access mindfulness meditations, sleep education videos, and strategies to improve sleep quality during inpatient treatment
Post-Inpatient Treatment
Participants complete 6 videoconference sessions with a therapist to learn mindfulness and coping strategies for sleep disturbance and symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment with follow-up surveys at discharge, 8 weeks, and 12 weeks post-discharge
Treatment Details
Interventions
- Nite2Day+
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator